Medifast (MED) Cost of Revenue (2010 - 2026)

Medifast (MED) has 17 years of Cost of Revenue data on file, last reported at $24.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 22.85% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $103.4 million (down 27.12% YoY), and the FY2025 full-year result was $110.6 million, down 29.93% from the prior year.
• Cost of Revenue for Q1 2026 stood at $24.3 million, up from $23.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $131.7 million in Q2 2022 and bottomed at $23.0 million in Q4 2025.
• The 5-year median for Cost of Revenue is $47.4 million (2024), against an average of $61.6 million.
• The widest annual swing landed in 2022, when Cost of Revenue surged 31.02%; it then tumbled 53.75% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $103.6 million in 2022, then sank by 52.1% to $49.6 million in 2023, then sank by 37.99% to $30.8 million in 2024, then slipped by 25.43% to $23.0 million in 2025, then climbed by 5.8% to $24.3 million in 2026.
• The last three Cost of Revenue figures came in at $24.3 million (Q1 2026), $23.0 million (Q4 2025), and $27.2 million (Q3 2025), per Business Quant data.

Peer Comparison